BioBoyScout
Subscribe
Sign in
Home
White Papers
Notes
Disclosures
About
Latest
Top
Discussions
The Platform Gambit
Why Arrowhead Doesn’t Need a Buyer
Jun 15
•
BioBoyScout
2
3
Arrowhead’s AI Edge Isn’t the AI, It’s the Data
The Invisible Dataset Behind the Platform
Jun 8
•
BioBoyScout
Edit the Copy, Not the Original
The Investment Case for Reversible RNA Editing Over Permanent Gene Editing
Jun 4
•
BioBoyScout
4
May 2026
The INHBE Reset
Who actually leads the INHBE race after EASL?
May 27
•
BioBoyScout
1
The Fab Choice
How Arrowhead engineered subcutaneous brain delivery
May 26
•
BioBoyScout
1
1
The Acquisition of the Decade
Why Arrowhead’s TRiM platform makes it the most strategically important target in biotech
May 18
•
BioBoyScout
6
ARO-MAPT: Proof of Mechanism
How Biogen’s CELIA data validated tau-targeting therapy and strengthened the case for ARO-MAPT
May 14
•
BioBoyScout
3
ARO-MAPT: The Last Open Question
What TIDES revealed, what it doesn’t, and what Phase 1/2a still has to show
May 14
•
BioBoyScout
4
Q2 FY26 Reaction: What Arrowhead's Operational Commitments Reveal
Why the most telling disclosure from yesterday’s call wasn’t a number, it was a single sentence in Chris Anzalone’s prepared remarks
May 8
•
BioBoyScout
7
1
ARO-MAPT: The Setup
Why the 2026 Phase 1/2a Readout Is Built to Succeed
May 3
•
BioBoyScout
1
1
The Endgame
If ARO-MAPT Works, What Is Arrowhead Worth, and When?
May 3
•
BioBoyScout
2
1
Arrowhead 2026 Catalyst Calendar
Upcoming readouts through early 2027 — what to expect and what each outcome means for the thesis | Data cutoff: May 11, 2026
May 3
•
BioBoyScout
2
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
